Quinolone: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 4: | Line 4: | ||
| edition = Ninth | | edition = Ninth | ||
| editor = Hardman JG, Limberd LE, Molinoff PB, Ruddon RW, Alfred Goodman Gilman | | editor = Hardman JG, Limberd LE, Molinoff PB, Ruddon RW, Alfred Goodman Gilman | ||
| publisher = McGraw-Hill | year = 1996}}, pp. 1065-1068 | | publisher = McGraw-Hill | year = 1996}}, pp. 1065-1068</ref> | ||
==Mode of action== | ==Mode of action== | ||
Revision as of 19:42, 6 September 2009
In medicine, quinolones are antibiotics that are "a group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or nalidixic acid."[1] Nadixilic acid's effects are localized to the urinary tract, but it was the first quinolone in general use. The subsequent quinolones, with broader spectra, were fluorinated and are often called fluoroquinolones.[2]
Mode of action
Quinolones inhibit the enzyme DNA gyrase.
Classes
'Respiratory quinolones' are levofloxacin, gatifloxacin, or moxifloxacin. However, gatifloxacin can cause dysglycemia.[3]
'Antipseudomonal quinolones' are ciprofloxacin, levofloxacin
References
- ↑ Anonymous (2024), Quinolone (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Hardman JG, Limberd LE, Molinoff PB, Ruddon RW, Alfred Goodman Gilman, ed. (1996), Goodman & Gilman's The Pharmacological Basis of Therapeutics (Ninth ed.), McGraw-Hill, pp. 1065-1068
- ↑ Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C et al. (2006). "Outpatient gatifloxacin therapy and dysglycemia in older adults.". N Engl J Med 354 (13): 1352-61. DOI:10.1056/NEJMoa055191. PMID 16510739. Research Blogging.